FDA 483 - SRI Krishna Pharmaceuticals Ltd - Unit I - September 01, 2023
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Sri Krishna Pharmaceuticals Limited - UNIT-I, an API manufacturer in Hyderabad, India, was cited for numerous significant cGMP deficiencies during an FDA inspection. Issues include widespread failures in Quality Unit oversight, inadequate equipment cleaning and validation, deficient out-of-specification and complaint investigations, and an insufficient stability monitoring program. These observations indicate a systemic lack of control over critical manufacturing processes and data integrity.
ID · 6e5e2af0-2250-4586-b754-3b07e8f471ec